Eli Lilly weight loss therapy on track for NHS rollout in England

England’s National Health Service (NHS) on Thursday proposed to launch Eli Lilly’s (NYSE:LLY) weight loss therapy tirzepatide initially for patients expected to receive its maximum clinical benefit.

In an application to the National Institute for Health and Care Excellence (NICE), which sets drug policy for the NHS, the agency detailed plans to introduce the GLP-1 injectable to nearly a quarter of a million people within the first three years as part of a phased rollout.

According to its proposal, the drug, also known as Zepbound, will be offered to patients with a BMI of more than 40 kg/m2. Initially, those with at least three weight-related health conditions, including hypertension, obstructive sleep apnea, or cardiovascular disease, will be eligible for the treatment.

The program will then be widened to those with two weight-related problems and subsequently to cover those with only one weight-related health condition.

The proposal is subject to three weeks of public comments until Oct. 22, after which NICE will announce the final guidance on tirzepatide and obesity.